Литература. 
Статины в профилактике и лечении сердечно-сосудистых заболеваний

1. Болезни нервной системы. Руководство для врачей / Под ред. Н. Н. Яхно, Д. Р. Штульмана. — М.: Медицина, 2004. — Т.1. — С. 231−302.

2. Ворлоу Ч. П., Деннис М. С., ван Гейн Ж. и др. Инсульт. Практическое руководство для ведения больных: Пер. с англ. — СПб., 1998. — 629 с.

3. Виберс Д. О., Фейгин В. Л, Браун Р. Д. Руководство по цереброваскулярным заболеваниям: Пер. с англ. — М., 1999. — 672 с.

4. Кузнецов В. В. Статины в системе реабилитации больных, перенесших атеротромботический ишемический инсульт // Врачебное дело. — 2006. — № 5−6 (1086). — С. 34−38.

5. Шевченко О. П., Праскурничий Е. А., Яхно Н. Н., Парфенов В. А. Артериальная гипертония и церебральный инсульт. — М., 2001. — 192 с.

6. Adams R.J., Chimowitz M.I., Alpert J.S. et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association // Stroke. — 2003. — Vol. 34. — P. 2310−2322.

7. Amarenco P., Bogousslavsky J., Amarenco P. et al. High-dose atorvastatin after stroke or transient ischemic attack // N. Engl. J. Med. — 2006. — 355. -Р. 549−59.

8. Amarenco P., Labreuche J., Lavalleґe P., Touboul P.-J. Statin in stroke prevention and carotid arteriosclerosis: systematic review and meta-analysis // Stroke. — 2004. — Vol. 35. — P. 2902−2909.

9. Amarenco P., Moskowitz M.A. The Dynamics of Statins: From Event Prevention to Neuroprotection // Stroke. — 2006. — Vol. 37. — P. 294−296.

10. Bays H. Statin safety: an overview and assessment of the data — 2005 // Am. J. Cardiol. — 2006. — Vol. 97. — P. 6−26.

11. Cannon C.P., Braunwald E., McCabe C.H. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes // N. Engl. J. Med. — 2004. — 350. — Р. 1495−504.

12. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins // Lancet. — 2005. — 366. — Р. 1267−78.

13. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial // Lancet. — 2004. — 364. — Р. 685−96.

14. Collins R., Armitage J., Parish S. et al. for the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions // Lancet. — 2004. — 363. — Р. 757−67.

15. Corti R., Fuster V., Fayad Z.A. Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions Two Years' Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging // Circulation. — 2002. — 106. — Р. 2884−87.

16. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study // JAMA. — 1998. — 279. — Р. 1615−22.

17. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum // J. Antibiot. (Tokyo). — 1976. — 29. — Р. 1346−8.

18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial // Lancet. — 2002. — 360. — Р. 8−22.

19. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) // Circulation. — 1998. — 97. — Р. 1440−5.

20. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, isсhemic heart disease, and stroke: systematic review and meta-analysis // BMJ. — 2003. — Vol. 326. — P. 1423−1430.

21. Liao J.K. Clinical implications for statin pleiotropy // Current Opinion in Lipidology. — 2005. — Vol. 16. — P. 624−629.

22. Lima J.A.C., Desai M.Y., Steen H. et al. Statin-induced Cholesterol Lowering and Plaque Regression after 6 Months of Magnetic Resonance Imaging-Monitored Therapy // Circulation. — 2004. — 110. — Р. 2336−41.

23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels // N. Eng. J. Med. — 1998. — 339. — Р. 1349−57.

24. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. A Randomized Controlled Trial // JAMA. — 2004. — 291. — Р. 1071−80.

25. Sacco R.L., Adams R., Albers G. et al. Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack: a Statement for Healthcare Professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline // Stroke. — 2006. — Vol. 37. — P. 577−617.

26. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study — a randomized controlled trial // JAMA. — 2001. — 285. — Р. 1711−8.

27. Shepherd J. et al. Prospective Study of Pravastatin in the Elderly at Risk Ongoing Trial (PROSPER) // Amer. J. Cardiology. — 1999. — Vol. 84. — P. 1192−1197.

28. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization // Stroke. — 2006. — Vol. 37. — P. 1923;1932.

29. Switzer J.A., Hess D.C. Statin therapy for coronary heart disease and its effect on stroke // Curr. Atheroscler. Rep. — 2006. — Vol. 8. — P. 337−342.

30. The Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. — 1994. — 344. — Р. 1383−89.

31. The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) // Cerebrovasc. Dis. — 2003. — 16. — Р. 389−95.